Individual Approach In Treatment Of Advanced Stomach Cancer
Abstract
Background: To study efficiency of the combined treatment of advanced gastric cancer with inclusion Trastuzumab.
Material: We present the intermediate analysis of the use of target therapy with Trastuzumab in patients with a HER2-positive gastric cancer. Up to 01.10.2009y 118 patients have been tested for HER-2 expression, and in 24 gastric cancer patients it is revealed HER2-positive status of tumor. It is lead chemotherapy to all patients by the PLF regimen and Herceptin in doze 6 mg/kg once in 3 weeks (6 cycles). In control group in 26 patients it is lead only chemotherapy by the PLF regimen once in 3 weeks without addition Trastuzumab (6 cycles).
Results: At the moment of the analysis of preliminary data, the median remission duration in compared groups has made 8.3 months, and 5.2 months, accordingly.
Conclusion: At advanced gastric cancer with high level HER-2 expression Trastuzumab increases frequency of objective effect and the median remission duration.
References
Aksel E. M. Condition of the oncological service to the population of Russia and the CIS countries in 2005 // Vestnik of N.N.Blohina of Russian Academy of Medical Science - 2007. - Т. 18, №2. – P. 8-51.
Davidov M. I., Aksel E. M. Death rate of the population of Russia and CIS countries from malignant tumors in 2005 // Vestnik of N.N.Blohina of Russian Academy of Medical Science, 2007. - Т.18, №2, - P. 90-120.
Karaseva V.V., Jerlov G.K., Lazerev A. F. The combined chemotherapy in disseminated stomach cancer // Russian ocological journal. - 2004. - №5. - P. 28-30.
Andrés Cervantes, Rosello S., Roda D. et al. The treatment of advanced gastric cancer: current strategies and future perspectives // ESMO Conference Lugano. Switzerland, (Lugano), 2008. Symposium lecture. - P. 103-107.
American Cancer Society. Global Cancer Facts and Figures 2007
Ohtsu A. J Gastroenterol 2008; 43:256-264
Hofmann M, Stoss O, Shi D, Buttner R, van d, V, Kim W et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52 (7):797-805.
Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51 (8):1371-1379.
Sasako M. Multimodal treatment of resectable gastric cancer: The Asian view // 10th World Congress on Gastrointestinal Cancer. Spain, (Barcelona), 2008. - P.153-161.
Van Cutsem et al. Abstract #7BA ECCO/ESMO 2009
Copyright information
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (Creative Commons Attribution License 3.0 - CC BY 3.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
info@cbuni.cz, www.cbuni.cz, ojs.journals.cz
